It is very uncertain whether endovenous laser ablation (EVLA) changes long‐term recurrence (> 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).
Endovenous laser ablation (EVLA) showed no clear difference in technical success (< 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (low certainty).
It is very uncertain whether endovenous laser ablation (EVLA) changes recurrence (< 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).
Endovenous laser ablation probably leads to lower recanalisation or persistence of reflux at 6 weeks compared with conventional surgery (moderate certainty).
Endovenous laser ablation may leads to lower recurrence of reflux at 1 year compared with conventional surgery (low certainty).
Endovenous laser ablation showed no clear difference in clinical evidence of recurrence after 1 year compared with conventional surgery (low certainty).